New Stock Announcement | Betta Pharmaceuticals (300558.SZ) has once again submitted an application to the Hong Kong Stock Exchange.

According to a disclosure from the Hong Kong Stock Exchange on August 28, Betta Pharmaceuticals Co., Ltd. (referred to as Betta Pharmaceuticals, 300558.SZ) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with CITIC SEC as its sole sponsor. The prospectus shows that Betta Pharmaceuticals is a major player in the innovative drug research and development industry in China, successfully transforming from a biotechnology company focused on drug discovery and development to a biopharmaceutical company entering the full industry chain and commercialization stage. Along with this transformation, the company has built an operational platform driven by the synergy of four key components: independent research and development, market expansion, strategic cooperation, and ecosystem construction. Since the launch of its first product in 2011, the company has achieved profitability for several consecutive years.